Analysts Set Twist Bioscience Corporation (NASDAQ:TWST) Target Price at $46.50

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $46.50.

A number of research analysts have recently issued reports on the stock. Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, February 3rd. Evercore boosted their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 3rd. Barclays boosted their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday, March 27th. Finally, TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th.

Twist Bioscience Trading Down 4.6%

NASDAQ TWST opened at $48.84 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. The firm has a market cap of $2.99 billion, a PE ratio of -38.16 and a beta of 2.20. Twist Bioscience has a one year low of $23.30 and a one year high of $57.88. The firm’s fifty day moving average is $47.64 and its two-hundred day moving average is $37.92.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business had revenue of $103.70 million during the quarter, compared to analyst estimates of $100.32 million. The business’s revenue was up 16.9% compared to the same quarter last year. Analysts expect that Twist Bioscience will post -2.12 earnings per share for the current year.

Insider Buying and Selling

In other Twist Bioscience news, CFO Adam Laponis sold 7,000 shares of the company’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $50.00, for a total value of $350,000.00. Following the sale, the chief financial officer owned 130,031 shares of the company’s stock, valued at $6,501,550. This represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Melissa A. Starovasnik sold 1,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $51.00, for a total transaction of $51,000.00. Following the completion of the sale, the director directly owned 25,722 shares in the company, valued at $1,311,822. This trade represents a 3.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 46,452 shares of company stock valued at $2,189,153. 3.08% of the stock is owned by company insiders.

Institutional Trading of Twist Bioscience

Several institutional investors and hedge funds have recently modified their holdings of TWST. Quarry LP purchased a new stake in shares of Twist Bioscience in the third quarter valued at about $28,000. Smartleaf Asset Management LLC lifted its holdings in shares of Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after purchasing an additional 442 shares in the last quarter. Strategic Advocates LLC lifted its holdings in shares of Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after purchasing an additional 906 shares in the last quarter. SBI Securities Co. Ltd. lifted its holdings in shares of Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after purchasing an additional 571 shares in the last quarter. Finally, National Bank of Canada FI purchased a new stake in shares of Twist Bioscience in the third quarter valued at about $46,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.